|
|
 |
|
Viewing report
|
|
|
|
Analysis of AERS Data on AMD Therapeutics
Primus Analytics Pvt Ltd, March 2009, Pages: 102
This report provides a detailed analysis on the adverse events reported against the prescribed AMD drugs namely Lucentis, Macugen and Visudyne for the treatment of Wet age related macular degeneration (Wet AMD). It covers in-depth, the various aspects of these drugs in terms of the consequences from their consumption, keeping in line with the real-time data registered in the FDA AERS database.
Age-related macular degeneration is a degenerative condition of the macula (the central retina). It is the most common cause of vision loss in the United States in those 50 or older, and its prevalence increases with age. AMD is caused by hardening of the arteries that nourish the retina. This deprives the sensitive retinal tissue of oxygen and nutrients that it needs to function and thrive. As a result, the central vision deteriorates. Besides affecting older populations, AMD occurs in whites and females in particular. The disease also can result as a side effect of some drugs, and it seems to run in families. Macular degeneration is diagnosed as either dry (non-neovascular) or wet (neovascular).
Dry AMD is an early stage of the disease and may result from the aging and thinning of macular tissues, depositing of pigment in the macula or a combination of the two processes. Wet AMD refers to growth of new blood vessels in an area, such as the macula, where the Wet they are not supposed to be. The dry form is more common than the wet, with about 85 percent of AMD patients diagnosed with dry AMD. The wet form of the disease usually leads to more serious vision loss.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
